# A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)

> **NCT02694978** · PHASE3 · COMPLETED · sponsor: **AMAG Pharmaceuticals, Inc.** · enrollment: 2014 (actual)

## Conditions studied

- Iron Deficiency Anemia

## Interventions

- **DRUG:** Ferumoxytol
- **DRUG:** FCM

## Key facts

- **NCT ID:** NCT02694978
- **Lead sponsor:** AMAG Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-29
- **Primary completion:** 2017-01-16
- **Final completion:** 2017-07-17
- **Target enrollment:** 2014 (ACTUAL)
- **Last updated:** 2023-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02694978

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02694978, "A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT02694978. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*